Knight Cancer Institute Researchers Report Research in Cell Transplants [Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation,...].
In: Immunotherapy Weekly, 2023-09-05, S. 1252-1252
serialPeriodical
Zugriff:
Keywords: Adrenal Cortical Steroids; Antineoplastics; Biomedicine; Cell Transplantation; Cell Transplants; Daratumumab Therapy; Dexamethasone Therapy; Drugs and Therapies; Glucocorticoids; Health and Medicine; Hematology; Hematopoietic; Hormones; Immunologic Agents; Immunotherapy; Lenalidomide Therapy; Monoclonal Antibodies; Ophthalmic Preparations; Ophthalmic Steroids; Pharmaceuticals; Surgery; Transplant Medicine EN Adrenal Cortical Steroids Antineoplastics Biomedicine Cell Transplantation Cell Transplants Daratumumab Therapy Dexamethasone Therapy Drugs and Therapies Glucocorticoids Health and Medicine Hematology Hematopoietic Hormones Immunologic Agents Immunotherapy Lenalidomide Therapy Monoclonal Antibodies Ophthalmic Preparations Ophthalmic Steroids Pharmaceuticals Surgery Transplant Medicine 1252 1252 1 09/04/23 20230905 NES 230905 2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on cell transplants are presented in a new report. For more information on this research see: Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Knight Cancer Institute Researchers Report Research in Cell Transplants [Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation,...].
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2023-09-05, S. 1252-1252 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Sonstiges: |
|